Morgan Stanley lowers Insmed stock target from USD 218.00 to USD 213.00

Published on 10/24/2026 at 20:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insmed reports third-quarter results on October 29, 2026. Insmed stock costs EUR 83.36 on October 24, 2026 at Lang & Schwarz in Berlin.

Analyst view and calendar

Morgan Stanley lowered its Insmed target to USD 213.00 from USD 218.00 on October 21, 2026.
Insmed will report third-quarter 2026 results on October 29, 2026.
Insmed stock costs EUR 83.36 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

INSM, US4576693075, Illustration mit AI erstellt.

Insmed (ISIN US4576693075) has received a lower price target from Morgan Stanley ahead of its next results. On October 21, 2026, Markets Insider reported that Morgan Stanley cut its target from USD 218.00 to USD 213.00 while retaining an Overweight rating. The revised target is 128.08 percent above the Nasdaq price of USD 93.39. Insmed was trading at EUR 83.36 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Target cut meets a busy calendar

The analyst change arrives before a scheduled reporting date. Insmed said on October 5, 2026 that it will publish third-quarter 2026 financial results on October 29, 2026, followed by an investor call at 8:00 a.m. ET. The release also said Chief Financial Officer Sara Bonstein will step down on October 30, 2026.

Nasdaq price remains above its yearly low

On Nasdaq, Insmed last traded at USD 93.39 on October 23, 2026 at 4:00 p.m. EDT. The 52-week range was USD 90.39 to USD 212.75, placing the price 3.32 percent above the low and 56.10 percent below the high. The company had a market capitalization of USD 20.4 billion at that market timestamp.

Revenue guidance sets the next test

The October 29 report will test the commercial trajectory behind the valuation. In its October 5 release, Insmed reaffirmed full-year 2026 revenue guidance of USD 1.25 billion to USD 1.40 billion for BRINSUPRI and USD 450.00 million to USD 470.00 million for ARIKAYCE. Those ranges provide the clearest operating benchmarks for the upcoming results.

What matters before October 29?

The contrast is straightforward: Morgan Stanley reduced its target by USD 5.00, while the company is approaching a dated earnings event with two product revenue ranges already defined. The next report can therefore add operating evidence to an analyst view that remains materially above the Nasdaq price.

Stock and reporting dates

Insmed was trading at EUR 83.36 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The Nasdaq reference price was USD 93.39 on October 23, 2026 at 4:00 p.m. EDT, while the next scheduled results date is October 29, 2026. The further course of trading is shown by the continuously updated real-time quote of Insmed stock.